Instructions for use, contraindications, composition and price of Nimotop

Nimotop is a calcium channel blocker used to treat to prevent brain damage caused by reduced blood flow due to aneurysm. Active ingredient: Nimodipine.

Pharmacological groups of Nimotop

Blocker «slow» calcium channels (BCCI). Calcium channel blockers
Blocker «slow» calcium channels (BCCI). Corrector disturbance of cerebral circulation

The nosological classification (ICD-10) of Nimotop

F60.3 Emotionally unstable personality disorder
G45.9 Transient cerebral ischemic attack, unspecified
I60 Subarachnoid haemorrhage
R41.3.0 * Reduced memory
R41.8.0 * Disorders intellectual mnesticheskie
R54 Senility

NIMOTOP

NIMOTOP

The drug forms of Nimotop

Tablets: Round, biconvex, yellow film-coated. On the front side of the tablet — engraved in the form of a Bayer cross on the back — «SK». The break — off-white homogeneous mass, surrounded by a yellow jacket.

The solution: a transparent, slightly yellow.

Pharmacologic effect of Nimotop

Mode of action — neuroprotection, vasodilator.

Indications for use of Nimotop

Common for both dosage forms

Prevention and treatment of ischemic neurological disorders caused by cerebrovascular spasm, against a background of subarachnoid hemorrhage due to the rupture of the aneurysm (tablets, film-coated, applied after the previous holding in / therapy infusion solution).

For tablets, film-coated (optional)

Expressions of brain function in elderly patients (loss of memory and concentration, emotional instability).

Contraindications of Nimotop

Tablets, film-coated

hypersensitivity to any component of the drug;

severe hepatic impairment (eg cirrhosis);

co-administration with rifampicin or anticonvulsants (phenobarbital, phenytoin, carbamazepine);

pregnancy;

breastfeeding;

age 18 years.

Solution for infusion

The only absolute contraindication is idiosyncrasy.

Note

Common for both formulations

hypotension (Garden

Patients with unstable angina or within the first 4 weeks after an acute myocardial infarction — an evaluation of the potential risks of (a decrease of perfusion of the coronary arteries and myocardial ischemia) and benefits (improvement in cerebral perfusion);

Tablets, film-coated

elderly patients with comorbidity with severe renal impairment (glomerular filtration rate

elderly patients with severe heart failure who receive the drug for the treatment of brain functions (regular examination should be carried out).

Solution for infusion

bradycardia;

myocardial ischemia;

severe heart failure;

increased intracranial pressure;

generalized swelling of the brain;

liver and kidney failure.